SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novartis Reports First RAE346 Phase I/II Data Since Acquisition

Novartis reported Phase I/II data for RAE346 in HR+/HER2- breast cancer, marking the first results since its acquisition.

Related stories